Is metabolic syndrome a risk factor in hepatectomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic manifestations

Abstract

Background Metabolic syndrome (MetS) is a risk factor in surgery. MetS can progress to metabolic (dysfunction)-associated fatty liver disease (MAFLD), a vast-growing etiology of primary liver tumors which are major indications for liver surgery. The aim of this meta-analysis was to investigate the impact of MetS on complications and long-term outcomes after hepatectomy. Methods The protocol for this meta-analysis was registered at PROSPERO prior to data extraction. MEDLINE, Web of Science, and Cochrane Library were searched for publications on liver resections and MetS. Comparative studies were included. Outcomes encompassed postoperative complications, mortality, and long-term oncologic status. Data were pooled as odds ratio (OR) with a random-effects model. Risk of bias was assessed using the Quality in Prognostic Studies tool (QUIPS), and the certainty of the evidence was evaluated with GRADE. Subgroup analyses for patients with histopathologically confirmed non-alcoholic fatty liver disease (NAFLD) versus controls were performed. Results The meta-analyses included fifteen comparative studies. Patients with MetS suffered significantly more overall complications (OR 1.55; 95% CI [1.05; 2.29]; p=0.03), major complications (OR 1.97 95% CI [1.13; 3.43]; p=0.02; I2=62%), postoperative hemorrhages (OR 1.76; 95% CI [1.23; 2.50]; p=0.01) and infections (OR 1.63; 95% CI [1.03; 2.57]; p=0.04). There were no significant differences in mortality, recurrence, 1- or 5-year overall or recurrence-free survivals. Patients with histologically confirmed NAFLD did not have significantly more overall complications; however, PHLF rates were increased (OR 4.87; 95% CI [1.22; 19.47]; p=0.04). Recurrence and survival outcomes did not differ significantly. The certainty of the evidence for each outcome ranged from low to very low. Conclusion Patients with MetS that undergo liver surgery suffer more complications, such as postoperative hemorrhage and infection but not liver-specific complications—PHLF and biliary leakage. Histologically confirmed NAFLD is associated with significantly higher PHLF rates, yet, survivals of these patients are similar to patients without the MetS. Further studies should focus on identifying the tipping point for increased risk in patients with MetS-associated liver disease, as well as reliable markers of MAFLD stages and early markers of PHLF. Trial registration PROSPERO Nr: CRD42021253768

Innovation for the Sake of Innovation? How Does Robotic Hepatectomy Compare to Laparoscopic or Open Resection for HCC—A Systematic Review and Meta-Analysis

“…With MAFLD rising as the cause of HCC and NAFLD being associated with higher PHLF rates, an interesting question to examine is the influence of steatosis, fibrosis and NASH on outcomes in RAH versus LH or OH. This is particularly relevant, as obesity, frequently concurring in MAFLD patients, may pose an additional limitation for minimally invasive surgery, and the benefits of the RAH approach would be interesting to consider [ 6 ].…”

“…Although a sequential progression to cirrhosis is not a prerequisite, most non-tumor tissue in HCC patients has some degree of damage. A global problem on the rise is a metabolic dysfunction-associated liver disease (MAFLD), which is associated with an increased risk of post-hepatectomy liver failure (PHLF) in patients undergoing liver resection [ 6 ]. Cirrhosis is already an established factor for PHLF [ 7 ].…”

Comparative analysis of perioperative and long‐term outcomes of patients with hepatocellular carcinoma: Nonalcoholic fatty liver disease versus viral hepatitis

“…However, there remains no consensus on perioperative outcomes and long‐term survival following hepatectomy in NAFLD‐HCC patients. Some studies indicate that NAFLD patients may face higher postoperative complication rates and extended hospital stays, potentially leading to worse overall survival, while others report superior survival outcomes in comparison to patients with non‐NAFLD‐related HCC 8–10 . Additionally, there are findings suggesting that long‐term outcomes for NAFLD‐HCC may be comparable to or worse than those for HCC of other etiologies 8 …”

“…Some studies indicate that NAFLD patients may face higher postoperative complication rates and extended hospital stays, potentially leading to worse overall survival, while others report superior survival outcomes in comparison to patients with non-NAFLD-related HCC. [8][9][10] Additionally, there are findings suggesting that long-term outcomes for NAFLD-HCC may be comparable to or worse than those for HCC of other etiologies. 8 Therefore, this study aimed to investigate both perioperative outcomes and long-term survivals after hepatectomy for HCC in patients with NAFLD by comparing them with those in patients with hepatitis viral infection.…”

“…[8][9][10] Additionally, there are findings suggesting that long-term outcomes for NAFLD-HCC may be comparable to or worse than those for HCC of other etiologies. 8 Therefore, this study aimed to investigate both perioperative outcomes and long-term survivals after hepatectomy for HCC in patients with NAFLD by comparing them with those in patients with hepatitis viral infection.…”